Find Neurology Drugs in Phase III Clinical Development in UNITED STATES

Lead Product(s): Dihydroergotamine Mesylate

Therapeutic Area: Neurology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 28, 2020

Details:

The publication reports results from a Phase 1 study designed to investigate and compare the safety and PK of STS101, DHE liquid nasal spray (Migranal®), and intramuscular (IM) DHE injection in healthy subjects.

Lead Product(s): Meloxicam

Therapeutic Area: Neurology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 22, 2020

Details:

The assignment of this PDUFA goal date follows the FDA’s acceptance of Baudax’s latest complete response package relating to its 2019 complete response letter and appeal filing.

Lead Product(s): Tavapadon

Therapeutic Area: Neurology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 14, 2020

Details:

Studies to enroll approximately 1,200 patients to determine effectiveness of tavapadon across the full spectrum of early- and late-stage parkinson’s.